Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SCOLR Pharma has reported revenues of $1.24m for the third quarter ended 30 September 2010, a decrease of 53%, compared to $2.62m for the same period in 2009.
Subscribe to our email newsletter
Based in Bothell, Washington, SCOLR Pharma is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter and nutritional products.
SCOLR Pharma has posted a net loss of $ $8.7m for the third quarter 30 September 2010, or $0.02 per diluted share, compared to net loss of $1.6m, or $0.04 per diluted share, for the comparable period in 2009.
SCOLR Pharma has reported an operating income of $8.69m, compared to $1. 58 for the same period in 2009.
For the nine months ended 30 September 2010, the company has posted total revenues of $5.13m, compared to $6.64 for the year ago period.
SCOLR Pharma has posted a net loss of $2.40m, or $0.05 per diluted share, compared to $5.06m, or $0.12 per diluted share, for the year ago period and operating loss was $2.39m, compared to $5.07 for the year ago period.
SCOLR Pharma president and CEO Stephen Turner said that their focus for the remainder of the year will be to continue executing the plans for their extended release nutritional supplement and drug delivery businesses, which have both been advanced in the last quarter.